Pyxis Oncology

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

To improve the lives of cancer patients by developing and delivering highly effective, personalized cancer treatments that extend survival and improve quality of life.

To become a world leader in cancer treatments and therapies by harnessing the power of personalized medicine and providing unparalleled diagnostic and therapeutic solutions.

We pride ourselves on being at the forefront of cancer research and therapeutic development. We have won numerous awards for our research and clinical trial programs, including the Breakthrough Awards for Excellence in Drug Development from the Cancer Research Institute and the National Cancer Institute's Inventor of the Year Award.